logo
Donald Trump Doubles Down on Mathematically Impossible Drug Price Cuts

Donald Trump Doubles Down on Mathematically Impossible Drug Price Cuts

Newsweek16 hours ago
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources.
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
President Donald Trump has doubled down on his claim of reducing drug prices by amounts that are mathematically impossible.
Trump told reporters on Sunday that his administration had cut the price of some prescription drugs by as much as 1,500 percent.
"Well, one of the things they're going to be talking about pretty soon are the tremendous drop in drug prices. You know, we've cut drug prices by 1,200, 1,300, 1,400, 1,500 percent. I don't mean 50 percent. I mean 14-, 1,500 percent," the president said.
When asked to clarify the president's remarks, White House spokesperson Kush Desai told Newsweek, "It's an objective fact that Americans are paying exponentially more for the same exact drugs as people in other developed countries pay, and it's an objective fact that no other Administration has done more to rectify this unfair burden for the American people."
Why It Matters
Trump's remarks signal a misunderstanding of how pricing and percentages work, which could undermine public confidence in his ability to tackle problems such as drug pricing.
President Donald Trump speaks with reporters near Air Force One at the Lehigh Valley International Airport in Allentown, Pennsylvania, on August 3.
President Donald Trump speaks with reporters near Air Force One at the Lehigh Valley International Airport in Allentown, Pennsylvania, on August 3.What To Know
Reducing the price of a drug by 100 percent would make it free, and a reduction greater than 100 percent suggests pharmaceutical companies would pay their customers to take their prescription drugs.
Commenting on Trump's claims, Jeffrey Frankel, a professor of capital formation and growth at Harvard University, told Newsweek that the numbers were "indeed mathematically impossible."
On Friday, the president made similar claims of bringing drug prices down by "1,000 percent, 1,200 percent" in an interview with Newsmax's Rob Finnerty.
That came a day after the White House said Trump had written to the heads of 17 pharmaceutical companies outlining steps they needed to take to bring down the prices of drugs sold in the U.S. to match the lowest price paid by a group of other economically advanced countries.
According to a fact sheet the White House released on Thursday, Trump's letters said the pharmaceutical manufacturers' proposals for implementing his May executive order—which seeks to achieve "most favored nation" pricing in the United States—had "fallen short."
However, it did not mention the percentage reductions the president has discussed in recent days.
What People Are Saying
Jeffrey Frankel, a professor of capital formation and growth at Harvard University, told Newsweek: "They are indeed mathematically impossible. If he cut prices 90 percent, the drugs would cost 1/10 as much as before. If 100 percent, then they would cost zero. If cutting 1,000 percent means a thing, then it means that the drug company pays you (a lot) to take the drug."
He added: "It's almost as if Trump is making fun of his supporters, seeing what increasingly absurd statements he can get away with."
Justin Wolfers, a professor of economics and public policy at the University of Michigan, told Newsweek: "This is not a question for an economist, but rather a sixth grader. After all, the Common Core curriculum standard 6.RP.3.c states that students should know how to 'find a percent of a quantity as a rate per 100 (e.g., 30 percent of a quantity means 30/100 times the quantity).'"
Wolfers added: "I just checked with my sixth grader (Oliver Wolfers), and he confirmed that he has studied percentages and that the president's math does not make sense 'because then the prices would be negative.' He added, 'Is he an idiot?' before returning to watching YouTube. Oliver's father agrees with Oliver's mathematical analysis and encourages him to use more positive language when engaging with fellow kids."
Pau Pujolas, a professor of economics at McMaster University, told Newsweek: "If your grocery bill is $100 and you get a 50 percent reduction in price, you pay $50. If you get a 75 percent reduction, you pay $25. If you get a 99 percent reduction, you pay $1. If you get a 100 percent reduction, you pay $0. You can't get a reduction larger than that ... so 1,200 percent doesn't make sense.
"Talking about bad math: Firing Erika McEntarfer, the director of the Bureau of Labor Statistics (BLS), is way worse than a POTUS not knowing how to operate with basic percentages. Let's not miss the forest for the trees."
President Donald Trump said at a Republican dinner in July: "This is something that nobody else can do. We're gonna get the drug prices down—not 30 or 40 percent, which would be great, not 50 or 60 percent. No, we're gonna get them down 1,000 percent, 600 percent, 500 percent, 1,500 percent. Numbers that are not even thought to be achievable."
The White House fact sheet said: "From this point forward, President Trump will only accept from drug manufacturers a commitment that provides American families immediate relief from vastly inflated drug prices and an end to the freeriding by European and other developed nations on American innovations."
Journalist James Surowiecki wrote on X in response to Trump's comments on Sunday: "It's not just that the math here is nonsensical. It's that Trump hasn't actually cut drug prices yet at all. He's literally just sent letters to drugmakers telling them to cut prices. Does he know that and is lying? Or is he deluded? We have no idea."
What Happens Next
Trump and the White House have not clarified what he means when he says drug prices will come down by as much as 1,500 percent.
The president's letters to pharmaceutical companies give them a 60-day window to present a viable plan to reduce U.S. drug prices.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Asian shares track rally on Wall Street that won back most of Friday's wipeout
Asian shares track rally on Wall Street that won back most of Friday's wipeout

Yahoo

time9 minutes ago

  • Yahoo

Asian shares track rally on Wall Street that won back most of Friday's wipeout

BANGKOK (AP) — Asian shares advanced on Tuesday, following U.S. stocks higher after they won back most of their sharp loss from last week. Investors appeared to have recovered some confidence after worries over how President Donald Trump's tariffs may be punishing the economy sent a shudder through Wall Street last week. At the same time, a stunningly weak U.S. jobs report Friday raised expectations that the Federal Reserve will cut interest rates at its next meeting in September, potentially a plus for markets. This week's highlights will likely include earnings reports from The Walt Disney Co., McDonald's and Caterpillar, along with updates on U.S. business activity. In Asian trading, Tokyo's Nikkei 225 index gained 0.6% to 40,515.81, while the Kospi in South Korea jumped 1.4% to 3,192.57. In Hong Kong, the Hang Seng rose 0.3% to 24,799.67. The Shanghai Composite index was up 0.5% at 3,602.13. Australia's S&P/ASX 200 jumped 1.1% to 8,759.90, while the SET in Thailand also gained 1.1%. India's Sensex was the sole outlier, losing 0.5% on concerns over trade tensions with the United States, with the Trump administration insisting on cutbacks in oil purchases from Russia. India has indicated that it will continue buying oil from Russia, saying its relationship with Moscow was 'steady and time-tested,' and that its stance on securing its energy needs is guided by the availability of oil in the markets and prevailing global circumstances. 'Trump's threats of 'substantial' tariff hikes on account of imports of Russian crude pose a quagmire for India,' Mizuho Bank said in a commentary. 'Between exacerbated U.S.-imposed geo-economic headwinds and financial/macro setbacks from Russian oil advantages lost, pain will be hard to avert.' On Monday, the S&P 500 jumped 1.5% to 6,329.94. The Dow Jones Industrial Average climbed 1.3%, or 585.06 points, to 44,173.64. The Nasdaq composite leaped 2% to 21,053.58. Idexx Laboratories helped Wall Street recover from its worst day since May, soaring 27.5% after the seller of veterinary instruments and other health care products reported a stronger profit for the spring than analysts expected. The pressure is on U.S. companies to deliver bigger profits after their stock prices shot to record after record recently. Reports from big U.S. companies have largely come in better than expected and could help steady a U.S. stock market that may have been due for some turbulence. A jump in stock prices from a low point in April had raised criticism that the broad market had become too expensive. Tyson Foods likewise delivered a bigger-than-expected profit for the latest quarter, and the company behind the Jimmy Dean and Hillshire Farms brands rose 2.4%. They helped make up for a nearly 3% loss for Berkshire Hathaway after Warren Buffett's company reported a drop in profit for its latest quarter from a year earlier. The drop-off was due in part to the falling value of its investment in Kraft Heinz. American Eagle Outfitters jumped 23.6% after Trump weighed in on the debate surrounding the retailer's advertisements, which highlight actor Sydney Sweeney's great jeans. Some critics thought the reference to the blonde-haired and blue-eyed actor's 'great genes' may be extolling a narrow set of beauty standards. 'Go get 'em Sydney!' Trump said on his social media network. Wayfair climbed 12.7% after the retailer of furniture and home decor said accelerating growth helped it make more in profit and revenue during the spring than analysts expected. Tesla rose 2.2% after awarding CEO Elon Musk 96 million shares of restricted stock valued at approximately $29 billion. The move could alleviate worries that Musk may leave the company. In other dealings early Tuesday, U.S. benchmark crude oil shed 9 cents to $66.20 per barrel while Brent crude, the international standard, gave up 8 cents to $68.68 per barrel. The U.S. dollar was unchanged at 147.09 Japanese yen. The euro slipped to $1.1555 from $1.1573. ___ AP Business Writers Stan Choe and Matt Ott contributed. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Those who invested in Castings (LON:CGS) five years ago are up 9.0%
Those who invested in Castings (LON:CGS) five years ago are up 9.0%

Yahoo

time9 minutes ago

  • Yahoo

Those who invested in Castings (LON:CGS) five years ago are up 9.0%

Ideally, your overall portfolio should beat the market average. But every investor is virtually certain to have both over-performing and under-performing stocks. So we wouldn't blame long term Castings P.L.C. (LON:CGS) shareholders for doubting their decision to hold, with the stock down 23% over a half decade. On top of that, the share price is down 5.9% in the last week. However, this move may have been influenced by the broader market, which fell 2.6% in that time. Since shareholders are down over the longer term, lets look at the underlying fundamentals over the that time and see if they've been consistent with returns. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement. During the five years over which the share price declined, Castings' earnings per share (EPS) dropped by 16% each year. The share price decline of 5% per year isn't as bad as the EPS decline. So investors might expect EPS to bounce back -- or they may have previously foreseen the EPS decline. The image below shows how EPS has tracked over time (if you click on the image you can see greater detail). Before buying or selling a stock, we always recommend a close examination of historic growth trends, available here. What About Dividends? As well as measuring the share price return, investors should also consider the total shareholder return (TSR). Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. Arguably, the TSR gives a more comprehensive picture of the return generated by a stock. In the case of Castings, it has a TSR of 9.0% for the last 5 years. That exceeds its share price return that we previously mentioned. This is largely a result of its dividend payments! A Different Perspective Investors in Castings had a tough year, with a total loss of 16% (including dividends), against a market gain of about 22%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Longer term investors wouldn't be so upset, since they would have made 1.7%, each year, over five years. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Even so, be aware that Castings is showing 2 warning signs in our investment analysis , and 1 of those is potentially serious... We will like Castings better if we see some big insider buys. While we wait, check out this free list of undervalued stocks (mostly small caps) with considerable, recent, insider buying. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on British exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store